Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Acumen Pharmaceuticals, Inc.

< Previous 1 2 Next >
News headline image
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD)
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Announces Pricing of Upsized $130 Million Public Offering
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals to Present Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease During Featured Research Session at the Alzheimer’s Association International Conference (AAIC®) 2023
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals to Participate in 2023 Bank of America Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals Presents in vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals to Participate in the Needham Neuroscience Forum
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients with Early Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals to Report Third Quarter 2022 Financial Results on Nov. 14, 2022
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193, an Anti-Amyloid Beta Oligomer Antibody for Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen’s ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted FDA Fast Track Designation for Alzheimer's Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
News headline image
Acumen Pharmaceuticals to Participate in Upcoming Investor and Scientific Conferences
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.